Cite
Stein S, Bogard E, Boice N, et al. Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases. Orphanet J Rare Dis. 2018;13(1):18doi: 10.1186/s13023-018-0761-2.
Stein, S., Bogard, E., Boice, N., Fernandez, V., Field, T., Gilstrap, A., Kahn, S. R., Larkindale, J., & Mathieson, T. (2018). Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases. Orphanet journal of rare diseases, 13(1), 18. https://doi.org/10.1186/s13023-018-0761-2
Stein, Susan, et al. "Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases." Orphanet journal of rare diseases vol. 13,1 (2018): 18. doi: https://doi.org/10.1186/s13023-018-0761-2
Stein S, Bogard E, Boice N, Fernandez V, Field T, Gilstrap A, Kahn SR, Larkindale J, Mathieson T. Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases. Orphanet J Rare Dis. 2018 Jan 22;13(1):18. doi: 10.1186/s13023-018-0761-2. PMID: 29357903; PMCID: PMC5778794.
Copy
Download .nbib